排序方式： 共有96条查询结果，搜索用时 31 毫秒
11.
QUN ZHAO SUNBOK LEE MARC KENT SCOTT SCHATZBERG SIMON PLATT 《Veterinary radiology & ultrasound》2010,51(2):122-129
We evaluated dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) in canine brain tumors. Magnetic resonance data sets were collected on seven canine intracranial tumors with a 3 T magnet using a T1‐weighted fast spin echo fluid attenuated inversion recovery sequence after an IV bolus injection (0.2 mmol/kg) of Gd‐DTPA. The tumors were confirmed histopathologically as adenocarcinoma (n=1), ependymoma (n=1), meningioma (n=3), oligodendroglioma (n=1), and pituitary macroadenoma (n=1) The data were analyzed using a two‐compartment pharmacokinetic model for estimation of three enhancement parameters, ER (rate of enhancement), Kel (rate of elimination), and Kep (rate constant), and a model‐free phenomenologic parameter initial area under the Gd concentration curve (IAUGC) defined over the first 90 s postenhancement. Pearson's correlations were calculated between parameters of the two methods. The IAUGC has a relatively strong association with the rate of enhancement ER, with r ranges from 0.4 to 0.9, but it was weakly associated with Kep and Kel. To determine whether any two tumors differed significantly, the Kolmogorov–Smirnov test was used. The results showed that there were statistical differences (P<0.05) between distributions of the enhancement pattern of each tumor. These kinetic parameters may characterize the perfusion and vascular permeability of the tumors and the IAUGC may reflect blood flow, vascular permeability, and the fraction of interstitial space. The kinetic parameters and the IAUGC derived from DCE‐MRI present complementary information and they may be appropriate to noninvasively differentiate canine brain tumors although a larger prospective study is necessary. 相似文献
12.
1-甲基环丙烯(1-MCP)是一种乙烯受体抑制剂,广泛应用于果蔬采后贮藏保鲜行业.本文从1-MCP在果蔬体内的吸收、与果实内部生物大分子互作及其机制、残留量及其法规约定等方面对1-MCP在果蔬体内的药代规律进行了分析.从产品开发和技术应用的角度概括了1-MCP常见的产品形式和发展趋势,梳理了1-MCP与预冷技术结合、与杀菌剂联用、与果蔬风味形成调控技术复合使用等多效保鲜技术的研发情况.通过概括分析可以发现,1-MCP的安全性高,残留量低,但有关其在果蔬体内的代谢规律和对果蔬品质的不利影响方面的研究较少,且大部分的研究集中于1-MCP的应用,长效稳定缓释剂型和复合保鲜技术将是今后的发展趋势. 相似文献
13.
为比较研究制备的伊维菌素长效透皮制剂与普通伊维菌素注射剂药物代谢及药效时间,本研究制备伊维菌素含量分别为0.5%、1.0%和1.5%的长效透皮制剂,采用高效液相色谱法检测不同药量相同体积伊维菌素长效透皮制剂和普通伊维菌素注射剂（1.0%）在家兔体内的药代动力学,并通过PKSolver药代动力学处理软件对数据进行分析。结果显示,0.5%、1.0%、1.5%伊维菌素长效透皮剂和1.0%普通注射剂吸收半衰期分别为0.81、0.52、1.02和0.12 d;达峰时间为1.55、0.97、1.62和0.42 d;峰浓度为47.36、72.02、115.30和99.53 ng/mL;消除半衰期为3.61、5.92、5.59和1.79 d;平均滞留时间为5.27、7.37、5.13和2.16 d;药时曲线面积为1 488.70、3 081.98、3 161.20和480.00 ng·d/mL,伊维菌素长效透皮剂体内维持有效药物浓度的时间长达35 d,普通注射剂仅为9 d。结果表明,伊维菌素长效透皮剂效果稳定,可进行更深入的研究。 相似文献
14.
在（26±1）℃的水温条件下,青虾一次性肌肉注射25mg／kg诺氟沙星后,用反相高效液相色谱法测定青虾血淋巴和肌肉组织中诺氟沙星含量。青虾血淋巴药一时曲线和肌肉药一时曲线均可以用二室开放模型来描述,诺氟沙星在青虾血淋巴液中的主要药动学参数为：分布相半衰期t1/α为1．66h,消除相半衰期t1/β为1．69h,达峰时间T（Peak）为1．82h,峰浓度C（max）为6．0081μg/mL,曲下面积AUC为30．75μg·mL^-1·h^-1,吸收相半衰期t1/2ka为1．66h。肌肉中的主要药动学参数为：分布相半衰期t1/ks为0．08h,消除相半衰期t1/2β为4．42h,达峰时间狄Peak）为0．03h,峰浓度C（max）为16．72μg/mL,曲下面积AUC为12．34μg·mL^-1·h^-1,吸收相半衰期t1/2a为0．08h。结果表明青虾肌注诺氟沙星后,能比较迅速的被吸收,并且在组织中维持较高的药物浓度。 相似文献
15.
Plasma and synovial fluid pharmacokinetics of a single intravenous dose of meropenem in adult horses
Vernon C. Langston Robin L. Fontenot Julie A. Byers Caroline M. Andrews Cathleen A. Mochal‐King 《Journal of veterinary pharmacology and therapeutics》2019,42(5):525-529
The objective of this study was to determine the pharmacokinetics of meropenem in horses after intravenous (IV) administration. A single IV dose of meropenem was administered to six adult horses at 10 mg/kg. Plasma and synovial fluid samples were collected for 6 hr following administration. Meropenem concentrations were determined by bioassay. Plasma and synovial fluid data were analyzed by compartmental and noncompartmental pharmacokinetic methods. Mean ± SD values for elimination half‐life, volume of distribution at steady‐state, and clearance after IV administration for plasma samples were 0.78 ± 0.176 hr, 136.1 ± 19.69 ml/kg, and 165.2 ± 29.72 ml hr‐1 kg?1, respectively. Meropenem in synovial fluid had a slower elimination than plasma with a terminal half‐life of 2.4 ± 1.16 hr. Plasma protein binding was estimated at 11%. Based on a 3‐compartment open pharmacokinetic model of simultaneously fit plasma and synovial fluid, dosage simulations were performed. An intermittent dosage of meropenem at 5 mg/kg IV every 8 hr or a constant rate IV infusion at 0.5 mg/kg per hour should maintain adequate time above the MIC target of 1 μg/ml. Carbapenems are antibiotics of last resort in humans and should only be used in horses when no other antimicrobial would likely be effective. 相似文献
16.
Luke A. Wittenburg Kristen Weishaar Dominique Ramirez Daniel L. Gustafson 《Veterinary and comparative oncology》2019,17(2):147-154
Doxorubicin (DOX) area‐under‐the‐curve (AUC) was calculated for 40 dogs with spontaneously occurring cancers using a previously validated limited‐sampling approach. All dogs were administered a dose of 30 mg/m2 by intravenous infusion and serum samples were collected at 5, 45 and 60 minutes post‐infusion. DOX and its major metabolite, doxorubicinol (doxol), were quantified in serum samples using high‐performance liquid chromatography tandem‐mass spectrometry. Wide interpatient variability was observed in the predicted DOX AUC with a coefficient of variation of 34%. A significant relationship was found between DOX AUC and absolute white blood cell count (P = 0.003), absolute neutrophil count (ANC; P = 0.002) and surviving fraction of neutrophils (P = 0.03) approximately 1 week after dosing (nadir). No changes in other hematologic parameters (red blood cells, platelets, lymphocytes, haemoglobin) were found to correlate with DOX AUC. The absolute dose (mg) and the dose per unit body weight (mg/kg) were not significantly correlated with nadir ANC. No relationships were found between maximum serum doxol concentration and myelosuppression. Baseline ANC was also significantly correlated to nadir ANC and a model was constructed using baseline ANC and DOX AUC that significantly described the nadir ANC. These findings demonstrate the important relationship between systemic DOX exposure and degree of neutropenia in dogs, and suggest a potential for individualized, pharmacokinetically‐guided DOX dosing in dogs. 相似文献
17.
Development of a multiroute physiologically based pharmacokinetic model for orbifloxacin in rabbits 
下载免费PDF全文
下载免费PDF全文 F. Yang F. Yang W. Shi H. Si T. Kong G. Wang J. Zhang 《Journal of veterinary pharmacology and therapeutics》2018,41(4):622-631
To predict the orbifloxacin concentrations in rabbits after multiple routes of administration, a flow‐limited multiroute physiologically based pharmacokinetic (PBPK) model was developed. Three routes of administration (IV, IM, and PO) were incorporated into this model. Physiological parameters including tissue weights and blood flows through different tissues were obtained from the literature. The tissue/plasma partition coefficients (PXs) for noneliminating tissues were calculated according to the area method, while the PXs for kidney and the rest of the body compartment, together with other parameters for absorption and elimination, were optimized based on the published concentrations. The comparisons between predicted and observed orbifloxacin concentrations proved its validity, and the present model predicted available concentration data well, including those in liver, kidney, muscle, lung, heart, and plasma after oral, intravenous, or intramuscular administration. A local sensitivity analysis was also performed, which showed that the parameters for oral absorption were most influential on the orbifloxacin concentrations. This model was used to predict plasma and tissue concentrations after multiple oral or intramuscular administration. This study demonstrated the feasibility of predicting drug residues in minor species after multiple routes of administration in the extra‐label manner using the PBPK modeling. 相似文献
18.
J. Wang T. Zhao X. Sun Y. Liu J. Zhu S. Zhang X. Cao 《Journal of veterinary pharmacology and therapeutics》2018,41(1):e49-e52
The objective of this study was to investigate the pharmacokinetic profile of tildipirosin (TD) in 24 beagle dogs following intravenous (i.v.) and intramuscular (i.m.) administration, respectively, at 2, 4, and 6 mg/kg. Plasma samples at certain time points (0–14 days) were collected, and the concentrations of drug were quantified by UPLC‐MS/MS. Plasma concentration–time data and relevant parameters were described by noncompartmental through WinNonlin 6.4 software. After single i.m. injection at 2, 4, and 6 mg/kg body weight, mean maximum concentration (Cmax) was 412.73 ± 76.01, 1,051 ± 323, and 1,061 ± 352 ng/ml, respectively. Mean time to reach Cmax was 0.36 ± 0.2, 0.08 ± 0.00, and 0.13 ± 0.07 hr after i.m. injection at 2, 4, and 6 mg/kg, respectively. The mean value of T1/2λz for i.m. administration at doses of 2, 4, and 6 mg/kg was 71.39 ± 28.42, 91 .33 ± 50.02, and 96.43 ± 45.02 hr, respectively. The mean residence times were 63.81 ± 10.96, 35.83 ± 15.13, and 38.18 ± 16.77 hr for doses of 2, 4, and 6 mg/kg, respectively. These pharmacokinetic characteristics after i.m. administration indicated that TD could be rapidly distributed into tissues on account of the high lipid solubility and then released into plasma. In addition, the absolute bioavailability of 2 mg/kg after i.m. injection was 112%. No adverse effects were observed after i.v. and i.m. administration. 相似文献
19.
研究了两种头孢噻呋注射液给猪肌注后的比较药物动力学特征。选用12头健康猪随机分为两组,每组6头,分别肌注上海公谊兽药厂生产的长效盐酸头孢噻呋注射液和美国辉瑞生产的盐酸头孢噻呋注射液（速解灵注射液）,每头5mg／kg。采用超高效液相色谱法测定猪血浆中头孢噻呋的的药物浓度,用Winnonlin5．2药动学分析软件非房室模型处理药时数据,模型200处理肌注给药后的药代动力学参数。结果表明：健康猪肌注两种注射液后,参数MRT、Cmax、tmax统计差异极显著（P〈0．01）,长效盐酸头孢噻呋注射液单剂量肌注给药较速解灵注射液吸收慢,达峰时间显著延迟,达峰浓度显著降低,平均驻留时间显著延长;参数AUC、Kel、t1/2允统计无显著性差异（P〉0．05）,长效盐酸头孢噻呋注射液的相对生物利用度为98．41％,与速解灵注射液的生物利用度相当。本研究可为头孢噻呋注射液的临床合理用药提供参考。 相似文献
20.
五种土霉素注射液在猪体内的药物代谢动力学比较研究 总被引：1，自引：1，他引：0
对五种土霉素注射液产品(A、B、C、D和得米先20%)进行了猪体内的药代动力学比较研究。五组猪分别按20 mg/kg的剂量耳后肌肉注射,HPLC测定血药浓度,3P97软件拟合血药浓度-时间数据,计算药代动力学参数。五种长效土霉素注射液均符合二室开放模型,峰浓度值分别为1.511、.772、.132、.022、.72μg/mL,AUC分别为48.456、0.22、52.41、66.045、9.8(μg.h)/mL。比较而言,得米先20%药动学最好,其次为产品C,产品B最差。 相似文献